PUBLICATION

Global Business Reports

AUTHORS

Alexander Stonor, Aya Turk

United States Life Sciences 2024

June 03, 2024

Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. Having experienced one of its hardest-ever years in 2023 – in terms of depressed valuations, public and private fundraising drought, and challenging geopolitical fluctuations – the US life sciences industry is now embracing recovery mode.

Yet, the US continues to dominate the global life sciences industry, and the largest pharmaceutical market in the world attracted numerous foreign players in 2023. US biopharma firms benefit from a supportive ecosystem of service providers but face upcoming challenges, notably from proposed regulatory changes. Amidst growing US-China tensions, the national security matter of domestic drug manufacturing may undergo significant reshaping. Despite challenges, the US keeps drawing on expertise from Ivy League institutions, Wall Street, and California's tech scene to drive innovation and maintain its premier status.

Drawing from almost a hundred interviews with biopharma, biotech, investors, CDMOs, CROs, specialty chemical, technology, and AI executives, the following pages present a comprehensive overview of the US life sciences industry today, and offer insights into the country’s capability to attract foreign capital, talent, and science. The report concludes by pondering the debate on the relationship between viruses and humanity, and how proactive investment in this area can lead to both returns and the well-being of our species.

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENT PUBLICATIONS

Southeast Asia Chemicals 2024

In an era of low-priced commodities and an uncertain geopolitical landscape, logistics companies are prioritizing the long-haul business, not just because it is probably the most profitable, but also because their customers are searching for new markets out to sea.

MORE PREVIOUSLY PUBLISHED

MACIG

"We plan to double our copper production by the end of the decade. There remains significant upside potential in the gold industry, and the copper operations are strategic and additive to that."

SUBSCRIBE TO OUR NEWSLETTER